🔗 Share this article

Given that the US proceeds with unprecedented changes to its vaccine schedules, one figure has emerged somewhat surprisingly: Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on COVID-19 vaccines throughout the global health crisis and has concentrated on potential fatalities after Covid immunization in her short position at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Vaccine Program

Health officials had intended to unveil major revisions to the pediatric vaccination calendar earlier this month, bringing the US with the Danish immunization schedule, it is understood – a major change that would place the US out of alignment with a large portion of the world with little proof for public health gain. The planned update has been pushed back until the new year.

Rather than the top vaccines chief, Høeg is scheduled to speak at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to head the office this calendar year.

A Shift at the Regulatory Body

The acting appointment might represent a tighter collaboration between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a increased emphasis upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for halting specific pediatric shot schedules in the US to become more like the Danish model, a society with comprehensive healthcare and a number of inhabitants roughly the size of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccines – usually the responsibility of Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Concerns Over Qualifications

Dr. Høeg has little discernible background in drug development, approval processes or administrative roles, which has been typical for previous heads of the biologics center. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She appears not to have the necessary background” for overseeing the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in leading a major agency. She has no expertise in industry regulation.”

Previous commissioners of the center would “understand laws and regulations and the science of drug development”, commented a former acting FDA commissioner. “Frankly, she has not acquired the type of experience that former directors who led the center have had.”

The drug center has an enormous workload at the FDA, Woodcock emphasized.

“Many people just focuses on the new drug program, but the off-patent medication office approves a multitude of off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and more, and each of these need to be supervised,” Dr. Woodcock explained. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant management component to the job, which manages in excess of 5,000 personnel. “It’s a huge leadership role, if you perform it correctly,” Woodcock added.

Official Statement and Contentious Programs

When asked about questions about Høeg’s fitness for the role and whether this assignment represents greater collaboration among FDA leaders on vaccines, a press secretary responded that the “concerns are based on flawed presumptions”.

“Her resume matches the functions of her position,” the official stated, citing the time Høeg spent guiding the agency head on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a contentious rapid therapy clearance system that reportedly worried her predecessors. “How are these therapies being chosen for this fast-track system? Who takes the calls?” Howard questioned. “There’s a lot of confidentiality going on at the FDA right now.”

In general, he remarked, “the agency looks to be trending towards more relaxed rules of most medications, except for immunizations.”

Documented Past Work on Immunizations

Regarding immunizations, Høeg has a more documented, if problematic, past, some experts observe. She released a research paper using non-validated crowd-sourced reports to assess the rate of myocarditis following Covid immunization. She advised the Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccinations are riskier than they are.

Part of her “desired changes” for the current administration encompassed altering regulations for recently developed shots and halting “non-essential” immunizations, she remarked following the vote on a online show. At the FDA, Høeg has according to sources proposed barring teenage boys from obtaining Covid vaccines.

“She is an thorough ideologue who begins with her preconceived notions and tailors the evidence to fit the science in a extremely disingenuous, dishonest fashion,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with fellow contrarians, {like|